Insulin-like growth factors inhibit dendritic cell-mediated anti-tumor immunity through regulating ERK1/2 phosphorylation and p38 dephosphorylation

Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen.

K Y Lin, Frank Guarnieri, Kevin F. Staveley-O’Carroll et al. · PubMed · 1996 · 1K citations

Medicine, Immunology, Oncology +17

Induction of the growth inhibitor IGF-binding protein 3 by p53

Leonard Buckbinder, Randy Talbott, Susana Velasco-Miguel et al. · Nature · 1995 · 877 citations

Life Sciences, Cancer Biology, Oncology +10

B7-H4 expression identifies a novel suppressive macrophage population in human ovarian carcinoma

Ilona Kryczek, Linhua Zou, Paulo C. Rodrı́guez et al. · The Journal of Experimental Medicine · 2006 · 737 citations · Full text

Life Sciences, Immunology, Oncology +17

In vivo antitumor activity of NVP-AEW541—A novel, potent, and selective inhibitor of the IGF-IR kinase

Carlos Garcı́a-Echeverrı́a, Mark Pearson, Andreas Marti et al. · Cancer Cell · 2004 · 538 citations · Full text

Medicine, Medicinal Chemistry, Oncology +9

Phase I, Pharmacokinetic, and Pharmacodynamic Study of AMG 479, a Fully Human Monoclonal Antibody to Insulin-Like Growth Factor Receptor 1

Anthony W. Tolcher, John Sarantopoulos, Amita Patnaik et al. · Journal of Clinical Oncology · 2009 · 307 citations

Pharmacy, Pharmacokinetics, Pharmacology +16